X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

"X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia."

"Underpinning the bull case: X4 raised $240.3 million in gross proceeds from two financings, extending its cash runway to end of 2028, while its 4WARD Phase 3 trial targets enrollment completion by Q3 2026 with a U.S. addressable market of approximately 15,000 patients in chronic neutropenia."

"Piper Sandler notes that timing for near-term clinical catalysts is tracking as expected, with updated ctDNA data and expanded Phase 2a survival data in first-line pancreatic cancer guided to Q2 and first half of 2026, respectively. The pivotal MAPKeeper 301 study remains on track for first patient dosing at mid-2026."

"The clinical data supporting that confidence is striking: atebimetinib delivered 64% overall survival at 12 months in first-line pancreatic cancer patients versus a roughly 35% benchmark"

X4 Pharmaceuticals, Immuneering, and a third biotech company have attracted institutional analyst attention with fresh initiations and maintained positive ratings. X4 Pharmaceuticals received a Guggenheim Buy initiation with a $12 price target, positioning mavorixafor as a differentiated hematology asset with Phase 3 development in chronic neutropenia. The company secured $240.3 million in financing, extending cash runway to end of 2028, with trial enrollment completion targeted for Q3 2026. Immuneering maintained an Overweight rating from Piper Sandler despite a modest price target reduction to $12. Clinical data shows atebimetinib delivering 64% overall survival at 12 months in first-line pancreatic cancer versus a 35% benchmark, with updated data and pivotal trial initiation expected throughout 2026.

Read at 24/7 Wall St.